Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.
Translational Psychiatry April 10, 2026 Ting-Hui Liu, Hong-Shiang Shen, Jheng-Yan Wu et al. 1 citation
This study aimed to evaluate the long-term effectiveness and safety of esketamine in adults with Major depressive disorder (MDD), focusing on suicide-related events, all-cause mortality, and major adverse cardiovascular events (MACEs). This target-trial simulation used the TriNetX Global Collaborative Network. Adults (≥ 18 years) with MDD who received either esketamine or a conventional...
DOI: 10.1038/s41398-026-04032-3 (opens in new tab)
Full text (opens in new tab)
Ketamine
Major depressive disorder
Humans
Antidepressive agents
+5